Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-...
Moderna cut R&D spending by about 31% last year, citing the wind-down of major phase 3 respiratory trials.
Why it mattersModerna's 31% R&D cut after winding down phase 3 respiratory trials requires reassessing near-term funding timelines.